Stock Research for CLDX

CLDX
Current Price

$2.3400


Latest Update: 2018-02-16 16:00:00

High
$ 2.3500
Low
$ 2.3400
Close
$ 2.3500
Volume
60743
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

CLDX Stock Chart & Research Data

The CLDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CLDX Due diligence Resources & Stock Charts

The CLDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLDX Detailed Price Forecast - CNN Money CNN View CLDX Detailed Summary - Google Finance
Yahoo View CLDX Detailed Summary - Yahoo! Finance Zacks View CLDX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CLDX Trends & Analysis - Trade-Ideas Barrons View CLDX Major Holders - Barrons
NASDAQ View CLDX Call Transcripts - NASDAQ Seeking View CLDX Breaking News & Analysis - Seeking Alpha
Spotlight View CLDX Annual Report - CompanySpotlight.com OTC Report View CLDX OTC Short Report - OTCShortReport.com
TradeKing View CLDX Fundamentals - TradeKing Charts View CLDX SEC Filings - Bar Chart
WSJ View Historical Prices for CLDX - The WSJ Morningstar View Performance/Total Return for CLDX - Morningstar
MarketWatch View the Analyst Estimates for CLDX - MarketWatch CNBC View the Earnings History for CLDX - CNBC
StockMarketWatch View the CLDX Earnings - StockMarketWatch MacroAxis View CLDX Buy or Sell Recommendations - MacroAxis
Bullish View the CLDX Bullish Patterns - American Bulls Short Pains View CLDX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CLDX Stock Mentions - StockTwits PennyStocks View CLDX Stock Mentions - PennyStockTweets
Twitter View CLDX Stock Mentions - Twitter Invest Hub View CLDX Investment Forum News - Investor Hub
Yahoo View CLDX Stock Mentions - Yahoo! Message Board Seeking Alpha View CLDX Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for CLDX - SECform4.com Insider Cow View Insider Transactions for CLDX - Insider Cow
CNBC View CLDX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLDX - OTC Markets
Yahoo View Insider Transactions for CLDX - Yahoo! Finance NASDAQ View Institutional Holdings for CLDX - NASDAQ


Stock Charts

FinViz View CLDX Stock Insight & Charts - FinViz.com StockCharts View CLDX Investment Charts - StockCharts.com
BarChart View CLDX Stock Overview & Charts - BarChart Trading View View CLDX User Generated Charts - Trading View


Latest Financial News for CLDX

3 Stocks That Could Put Tesla's Returns to Shame
Posted on Friday February 16, 2018

A small biotech, a Chinese tech giant, and the world's biggest coffee seller may be surprising choices to outgain Tesla. Keep reading to learn why they're on track to be better investments.


Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of Influence
Posted on Thursday February 15, 2018

NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, ...


Is Celldex Therapeutics, Inc. (CLDX) a Buy?
Posted on Wednesday January 31, 2018

The odds just might finally be in this biotech's favor.


What to Expect From Celldex Therapeutics, Inc. in 2018
Posted on Saturday January 27, 2018

After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell.


Celldex Therapeutics: Back Up The Truck Or Back Away?
Seeking Alpha - Feb 8, 2018
The stock is certainly risky given the monumental late-stage clinical failure of the company's glioblastoma immunotherapy Rintega with no other candidates in the pipeline in the final stages of development.
What The Investing World Hopes From Celldex Therapeutics, Inc. (CLDX), The ... - Post Analyst

Is Celldex Therapeutics, Inc. (CLDX) a Buy?
Motley Fool - Jan 31, 2018
Another example of the risk associated with investing in Celldex stock is what happened to the company in 2017. Last June, Celldex presented the phase 1 portion of data from a phase 1/2 study evaluating varlilumab in combination with Bristol-Myers ...

What to Expect From Celldex Therapeutics, Inc. in 2018
Motley Fool - Jan 27, 2018
In early 2016, the company's former lead candidate, Rintega, performed as expected for brain cancer patients, but those randomized into groups receiving standard chemo outperformed historical expectations by a mile.
Celldex Therapeutics, Inc., (NASDAQ: CLDX) – Evaluate Stock's Volatility ... - Stock Watch

Right After Earnings, The Intelligent Options Trade in Celldex Therapeutics Inc
CML News - 17 hours ago
The results here are provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation.

Enter a stock symbol to view the stock details.